AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells

Radiother Oncol. 2014 Aug;112(2):302-7. doi: 10.1016/j.radonc.2014.07.015. Epub 2014 Aug 20.

Abstract

Background and purpose: Cellular radioresistance is a major impediment to effective radiotherapy. Here, we demonstrated that long-term exposure to fractionated radiation conferred acquired radioresistance to tumor cells due to AKT-mediated enhanced aerobic glycolysis.

Material and methods: Two human tumor cell lines with acquired radioresistance were established by long-term exposure to fractionated radiation with 0.5 Gy of X-rays. Glucose uptake was inhibited using 2-deoxy-D-glucose, a non-metabolizable glucose analog. Aerobic glycolysis was assessed by measuring lactate concentrations. Cells were then used for assays of ROS generation, survival, and cell death as assessed by annexin V staining.

Results: Enhanced aerobic glycolysis was shown by increased glucose transporter Glut1 expression and a high lactate production rate in acquired radioresistant cells compared with parental cells. Inhibiting the AKT pathway using the AKT inhibitor API-2 abrogated these phenomena. Moreover, we found that inhibiting glycolysis with 2-deoxy-D-glucose suppressed acquired tumor cell radioresistance.

Conclusions: Long-term fractionated radiation confers acquired radioresistance to tumor cells by AKT-mediated alterations in their glucose metabolic pathway. Thus, tumor cell metabolic pathway is an attractive target to eliminate radioresistant cells and improve radiotherapy efficacy.

Keywords: 2-Deoxy-d-glucose; AKT; Glut1; Glycolysis; Radioresistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aerobiosis
  • Cell Death / drug effects
  • Chlorpropamide / analogs & derivatives
  • Chlorpropamide / pharmacology
  • Deoxyglucose / pharmacology
  • Glucose / metabolism
  • Glucose Transporter Type 1 / biosynthesis
  • Glycolysis
  • HeLa Cells
  • Hep G2 Cells
  • Humans
  • Lactates / metabolism
  • Neoplasms / enzymology
  • Neoplasms / metabolism*
  • Neoplasms / radiotherapy*
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Radiation Tolerance / physiology
  • Radiation Tolerance / radiation effects
  • Reactive Oxygen Species / metabolism

Substances

  • API 2
  • Glucose Transporter Type 1
  • Lactates
  • Protein Kinase Inhibitors
  • Reactive Oxygen Species
  • SLC2A1 protein, human
  • Deoxyglucose
  • Proto-Oncogene Proteins c-akt
  • Glucose
  • Chlorpropamide